A new consensus from Italian neurologists proposes enhancing the endocannabinoid system multiple sclerosis treatment approach for patients with relapse-free disease. The algorithm combines cannabinoid agents with lifestyle interventions to address residual symptoms like spasticity in MS patients on high-efficacy therapies.
Persistent and debilitating muscle spasms | Center for Medical Cannabis – Utah.gov
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic SpasticityClinical GuidelinesMultiple SclerosisDosing ProtocolsState Policy Why This MattersUtah's evidence-based guidelines represent a significant step...
Over 70% of MS patients in rehab take 5 or more medications, study finds
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Multiple SclerosisPolypharmacySpasticityPain ManagementNeurological Conditions Why This MattersThis polypharmacy finding in MS rehabilitation patients...
Honoring the trailblazers with MS who changed cannabis policy – Blog
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Multiple SclerosisSpasticityMedical Cannabis PolicyPatient AdvocacyNeuropathic Pain Why This MattersMultiple sclerosis patients were among the...
MS cases double in England over 20 years; life expectancy rises
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Multiple SclerosisSpasticityChronic PainNeurological ConditionsThc:Cbd Why This MattersThe doubling of MS cases alongside improved survival...
Investigating the effectiveness and adverse events of medicinal cannabis for patients with muscle spasticity or spasms.
Appropriate treatment of muscle spasticity and spasms is important as these conditions may significantly impair patients’ quality of life. Conventional pharm…
Cannabis for MS Spasticity: A Systematic Review With Critically Unreliable Pooled Estimates
Substantial heterogeneity (I² = 100% for overall and AS analyses; 91% for NRS) and asymmetry in funnel plots suggest possible publication bias and study variability.
Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.
The recent introduction of High-Efficacy Therapies (HETs) in clinical practice has drastically reduced the frequency of acute inflammatory episodes and relap…